Triptans, the pillar of migraine therapy, increase serotonin signaling in cranial blood vessels and nerve endings [36], relieving pain by inducing vasoconstriction and reducing the release of vasoactive peptides, such as the calcitonin-gene-related peptide (CGRP) and substance P (SP), among others [37,38]. The gene discussed is TFF2; the disease is migraine disorder.